Canaccord Genuity Group Forecasts Strong Price Appreciation for Niagen Bioscience (NASDAQ:NAGE) Stock

Niagen Bioscience (NASDAQ:NAGEGet Free Report) had its price target boosted by investment analysts at Canaccord Genuity Group from $13.00 to $16.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target points to a potential upside of 19.14% from the company’s current price.

Several other equities analysts have also issued reports on the company. Wall Street Zen lowered Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a research note on Friday. Roth Capital lifted their target price on Niagen Bioscience from $10.00 to $23.00 and gave the company a “buy” rating in a research report on Friday.

Get Our Latest Stock Analysis on NAGE

Niagen Bioscience Stock Performance

NASDAQ:NAGE opened at $13.43 on Tuesday. The firm has a market capitalization of $1.06 billion, a P/E ratio of 79.00 and a beta of 2.08. The company has a fifty day moving average of $8.69. Niagen Bioscience has a one year low of $2.31 and a one year high of $13.53.

About Niagen Bioscience

(Get Free Report)

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.

Recommended Stories

Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.